Powered by ATCOR™
SphygmoCor® XCEL is the heart of our MedX Platform—a full complement of ATCOR technologies for professional use by clinicians and scientific researchers.
But that’s just the start of our mission. We believe that our technology has much broader potential—global potential, far beyond professional healthcare.
If figures from WHO and other leading global health organizations are accurate, roughly half the population of the developed world has hypertension. In the US alone, 8 out of 10 first stroke victims and 7 out of 10 people with chronic heart failure have hypertension.
We have secured several key licensing and joint-development agreements—working with other technology providers to integrate our breakthrough cardiovascular measurements into digital and device-based consumer health solutions.
Our current focus is hypertension and cardiovascular disease—but we envision broad applications for large-scale, global population health disorders like obesity, diabetes management, and dementia—as well as mHealth monitoring, “quantified athlete,” and a host of general consumer health and wellness wearables. We’re calling these new, consumer-facing technology platforms HomeX and WearX—all POWERED by ATCOR.
We are developing a full suite of consumer- and patient-friendly versions of our NcBP-derived clinical parameters including:
- Heart Stress
- Heart Age
- Exercise Capacity
- Heart Rate Plus
- Irregular Heartbeat
- Arterial Stiffness
- Heat Rate Variability
- Blood Pressure
- Central Pulse Pressure
- Cardiac Efficiency
Comprehensive heart and arterial health score that reflects the impact of arterial stiffness across the cardiovascular system. Calculation of Arty™ takes into account Heart Stress (excess pressure to the heart), Heart Age (status of cardiovascular aging), Exercise Capacity (ability to supply oxygen), and Heart Rate Plus (beat-to-beat HR).
Breakthrough Algorithm Development for Monitoring
Heart & Arterial Health with Wearable Devices
HomeX Focus--Home BP Monitoring
Home BP devices are commonly used by patients who have been diagnosed with high blood pressure. But they are increasingly being used by health-conscious people trying to keep tabs. Home monitoring may also be recommended (if not prescribed) to monitor effects of drug therapies and lifestyle changes. Home BP monitoring provides a simple, un-intrusive, affordable alternative to ambulatory blood pressure monitoring.
Unlike ABPM, regular, standalone home BP devices do not monitor BP during sleep. And there are large variations in measurement accuracy since many home BP monitors are not properly validated or FDA-approved. While some home devices have undergone technical validation, the overall level of accuracy does not match ABPM.
ATCOR is actively engaged with several potential partners to develop a state-of-the-art home BP monitor with both brachial and central BP capabilities—as well as other NcBP-derived cardiovascular parameters at a market-competitive price point.
Watch this space.
WearX Focus—Wearable Health Monitors
The fastest-growing sector in healthcare technology hands-down is mHealth—especially wearable devices. The sector has quickly expanded from helping people monitor their health status at an activity/fitness level to a medical level, with the devices performing tests that are more commonly associated with a professional medical consultation.
A large sub-set of wearable health devices is the emerging technology that enables continuous ambulatory monitoring of human vital signs during all aspects of daily life—or in a clinical environment—while minimizing discomfort and interference with normal human activities.
Blood pressure is considered to be the most important cardiopulmonary parameter. A wearable device forms a type of ambulatory BP monitoring, bringing the advantage of more representative BP measurements and the ability to quickly respond to any anomalies. Not to mention creating an archivable data feed—a treasure trove of information that consumers can share with their doctor as part of a holistic health and wellness regimen.
Watch this space.